GLP1R and kidney disorder: In another meta-analysis [6] of clinical trials with renal outcomes, incorporating data from 42,920 patients, showed that GLP-1 receptor agonists reduced the risk of kidney disease progression, including macroalbuminuria, compared with placebo (HR, 0.82; 95% CI, 0.75–0.89).